Ultragenyx Pharmaceutical Inc.
RARE:NASDAQ
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Streetwise Company Fact Sheet2026/8/24 18:13:21
(RARE:NASDAQ)
Analyst coverage
| Wells Fargo & Co. — Benjamin Burnett |
| Guggenheim Securities LLC — Debjit Chattopadhyay |
| Wedbush — Dr. Laura Chico |
| Canaccord Genuity — Whitney Ijem |
| Cantor Fitzgerald — Kristen Kluska |
| Citi — Yigal Nochomovitz |
| H.C. Wainwright & Co. — Dr. Ram Selvaraju |
Streetwise Reports Articles
| 08/21/2026 - View Article |
Streetwise - Ultragenyx Pharmaceutical Inc. Ownership Overview*
Ultragenyx Pharmaceutical Inc. (RARE:NASDAQ)
Restructures
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 08/12/03 | RARE:NASDAQ | 2 | RARE:NASDAQ | 3 |
| 09/06/00 | RARE:NASDAQ | 2 | RARE:NASDAQ | 3 |
*Share Structure as of 8/20/2026
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
